Sunday, December 22, 2024
name of Prensa Latina
Bandera inglesa
English Edition
Search
Close this search box.
name of Prensa Latina

NEWS

NEWS

Work of Cuba’s Center for Genetic Engineering is acknowledged

FzzWsu2XsAEUZfZ
Havana, Jul 1 (Prensa Latina) Cuban Prime Minister Manuel Marrero on Saturday acknowledged the work and contributions to science from the Center for Genetic Engineering and Biotechnology (CIGB), on the occasion of the 37th anniversary of its creation.

On his Twitter account, the head of Government sent congratulations to the CIGB work group, founded on the initiative of the historic leader of the Cuban Revolution, Fidel Castro.

“You are the pride of our science. With your products, many human lives have been saved in Cuba and other parts of the world,” Marrero tweeted.

The CIGB has printed its name in the scientific history of Cuba and the world for the development of various drugs and vaccines, such as two of Cuba’s five homegrown immunogens against Covid-19: Mambisa and Abdala.

Abdala, the first vaccine created in Latin America, demonstrated 92.28-percent efficacy in its phase III of clinical trials and millions of doses have already been administered in Cuba and other countries like Venezuela, Nicaragua, the Sahrawi Arab Democratic Republic and Vietnam.

Data from the CIGB show that some 40 million doses of the Abdala vaccine were delivered to the Cuban Healthcare System for mass vaccination against Covid-19.

Mambisa, in turn, is among the vaccines designed globally to administer nasally and thus attack the main entry of the SARS-CoV-2 coronavirus, which causes Covid-19.

The Center has designed leading products such as the vaccine against hepatitis B, the skin growth factor, the Heberpenta vaccine and streptokinase, the latter was obtained for the first time in the world.

It also has to its credit one of the most internationally recognized medicines: Heberprot-P, a unique and exclusive drug designed to treat diabetic foot ulcers and reduce the risk of amputation.

jg/mem/mks

LATEST NEWS
RELATED